|
Symposium
[In-Person] Advances in Cancer Therapeutics
Speakers:
Alex Cacovean (Biomea Fusion), Eric Blouin, (Ipsos), Umer Raffat (Evercore), Amar Patel (BMS), Kelsey Gauthier (Arcus), Allison Roberts (Frontier Medicines), Jennifer Low (23andMe), Shiva Bhowmik (Trio Pharmaceuticals), Dirk Brockstedt (RAPT Therapeutics), Dara L. Burdette (Tempest Therapeutics), Cheng Liu (Eureka Therapeutics)
Organizers:
Toby Freedman (Synapsis Search Recruiting and Author), Joe Carlino (Carlino Consulting), Donald McCarthy (Samsara BioCapital), Betty Chang (Summit Therapeutics), Wenfeng Xu (Chantibody Therapeutics Inc), Snow Ge (BridgeBio Pharma), Shichang Miao (PBSS)
Date:
2023-09-21
Time:
8:45-18:30 Pacific Time
Registration fee:
Regular attendees: $195; Academic/Students/Postdocs/Between Jobs: $95; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $995; Lunch Sponsorship: $1250; On-site Registration:$500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(13)Aragen; ATUM; Biocytogen Boston Corp; Correlia Biosystems Inc; Curis Decontamination Systems; Ellegaard BioResearch; Emery Pharma; Frontage Laboratories; Inotiv; Meadowhawk Biolabs; PharmaBlock; Revvity; SOLVO/CRL
Registration: http://www.PBSS.org
Registration deadline:2023-09-19
(it will close sooner if the seating cap is reached)
About the Topic
This one-day symposium will discuss the latest advances in the discovery and development of cancer therapeutics from leading pharmaceutical companies and promising biotech companies.
Presenting Companies / Speakers:
- Bristol Myers Squibb-Amar Patel, MD, Senior Director, Early Clinical Development: Advancing Novel Modalities for the Treatment of Hematologic Cancers
- Arcus-Kelsey Gauthier, PhD, Director of Biology: Fc-Silent Anti-TIGIT Potentiates Anti-Tumor Immunity Without Depleting Regulatory T-Cells.
- Biomea Fusion-Alex Cacovean, MD, VP, Clinical Development: First-in-Class Covalent MENIN Inhibitors for AML.
- Evercore ISI-Umer Raffat, Fundamental Research Analyst, Biotech Senior Managing Director: ASCO Highlights.
- Ipsos Healthcare-Eric Blouin, SVP of Oncology: New Regulatory Approvals for Cancer Therapeutics and Their Clinical Impact – a Commercial Perspective
- Frontier Medicines-Allison Roberts, PhD, Senior Scientist,Chemical Biology: Challenging Cancer with Chemoproteomics—FMC-376, a Dual KRAS G12C Inhibitor.
- 23andMe-Jennifer Low, MD, PhD, Head of Therapeutics Development: Developing genetically-validated drugs using 23andMe's genetic database.
- Trio Pharmaceuticals-Shiva Bhowmik, PhD, founder nad COO: Novel Bispecific Antibody Drugs Eliminating Cancer Cells and Immunosuppressor Cells to Enhance Anti-Tumor Immunity.
- RAPT Therapeutics-Dirk Brockstedt, PhD, Chief Scientific Officer: CCR4 oncology program update
- Tempest Therapeutics-Dara L. Burdette, PhD, Executive Director: Weathering the Storm: Small Molecule Inhibitors of Diverse Targets as Novel Immune Oncology Therapies
- Eureka Therapeutics-Cheng Liu, PhD, Founder, President and CEO: Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T-Cell Receptor (AbTCR)
Morning Sessions:
|
Time (PT)
|
Topic
|
|
8:45-9:00 am
|
PBSS Welcome and Symposium Overview, Shichang Miao (PBSS)
|
|
9:00-9:35 am
|
1. Fc-Silent Anti-TIGIT Potentiates Anti-Tumor Immunity Without Depleting Regulatory T-Cells
Kelsey Gauthier, PhD, Director of Biology, Arcus Biosciences
|
|
9:35-10:10 am
|
2. Developing Genetically-Validated Drugs Using 23andMe’s Genetic Database
Jennifer Low, MD, PhD, Head of Therapeutics Development, 23andMe
|
|
10:10-10:45 am
|
3. Challenging Cancer With Chemoproteomics—FMC-376, a Dual KRAS G12C Inhibitor
Allison Roberts, PhD, Senior Scientist, Chemical Biology, Frontier Medicines
|
|
10:45-10:55 am
|
Major Sponsor’s Presentation (Fortrea CRO)
|
|
10:55-11:15 am
|
Break Period & Vendor Show
|
|
11:15-11:50 am
|
4. First-in-Class Covalent MENIN Inhibitors for AML
Alex Cacovean, MD, VP, Clinical Development, Biomea Fusion
|
|
11:50-12:25 pm
|
5. New Regulatory Approvals for Cancer Therapeutics and Their Clinical Impact – a Commercial Perspective
Eric Blouin, SVP Oncology, Ipsos Healthcare
|
|
12:25-1:15 pm
|
Lunch
|
Afternoon Sessions:
|
Time (PT)
|
Topic
|
|
1:15-1:50 pm
|
6. ASCO Highlights
Umer Raffat, Fundamental Research Analyst, Biotech Senior Managing Director, Evercore ISI
|
|
1:50-2:25 pm
|
7. Novel Bispecific Antibody Drugs Eliminating Cancer Cells and Immunosuppressor Cells to Enhance Anti-Tumor Immunity
Shiva Bhowmik, PhD, Founder & COO, Trio Pharmaceuticals
|
|
2:25-3:00 pm
|
8. Advancing Novel Modalities for the Treatment of Hematologic Cancers
Amar Patel, MD, Senior Director, Early Clinical Development, Bristol Myers Squibb
|
|
3:00-3:20 pm
|
Break
|
|
3:20-3:55 pm
|
9. Updates on CCR4 Antagonists for Oncology
Dirk Brockstedt, PhD, Chief Scientific Officer, RAPT Therapeutics
|
|
3:55-4:30 pm
|
10. Weathering the Storm: Small Molecule Inhibitors of Diverse Targets as Novel Immune Oncology Therapies
Dara L. Burdette, PhD, Executive Director, Tempest Therapeutics
|
|
4:30-5:05 pm
|
11. Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T-Cell Receptor (AbTCR)
Cheng Liu, PhD, Founder, President and CEO, Eureka Therapeutics
|
|
5:05-5:35 pm
|
Panel Discussion (All Speakers)
|
|
5:35-6:30 pm
|
Happy Hour (sponsored by Alturas Analytics)
|
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapies
|
2024-12-05, [Free Online] Innovative Mass Spectrometry and Related Technologies for Life Science and Drug Development
|
2024-12-13, Why All These New Modalities?
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
PharmaResources
Top-tier small molecule CRO/CDMO offering comprehensive supports from Medicinal Chemistry, DMPK, and CMC to GMP manufacturing for commercialization.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Simulations Plus
GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
|
Allucent
Bringing innovation to Biotech w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
|
Submit a Text Ad
|